Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
AbbVie
NORTH CHICAGO, IL
GATIFLOXACIN (gatifloxacin) by AbbVie is [ see microbiology ( ) ] . Approved for bacterial conjunctivitis caused by susceptible strains of the following organisms: haemophilus influenzae, staphylococcus aureus, staphylococcus epidermidis and 3 more indications. First approved in 2018.
Drug data last refreshed 22h ago
[ see Microbiology ( ) ] .
Worked on GATIFLOXACIN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects
Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo